We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Immunohistochemical Technology Enables in situ Biomarker Analysis

By Biotechdaily staff writers
Posted on 31 May 2007
An automated quantitative immunohistochemical (IHC) technology enables in-situ biomarker analysis for pathology.

A U.S. More...
patent has been issued to Yale University (New Haven, CT, USA) and is exclusively licensed to HistoRx (New Haven, CT, USA). The patent claims the Aqua technology process, particularly the Place (pixel locale assignment for compartmentalization of expression) method, whereby biomarker expression is quantified in specific compartments of cells in tissue sections such as biopsies. The invention protected by this patent is the result of work pioneered by David Rimm, M.D., Ph.D., and Robert Camp, M.D., Ph.D., both from Yale University School of Medicine.

Rana K. Gupta, Interim CEO of HistoRx said, HistoRx is already applying Aqua analysis, fluorescent IHC methods, and digital imaging techniques to develop multiparametric assays to segment patients prior to therapy. The rapidly increasing number of independent, peer-reviewed scientific publications confirms the growing recognition of the utility of the Aqua technology in drug research and development.

We are gratified to see this patent granted because we believe Aqua technology will play a significant role in the emergence of companion diagnostics by making it possible to ensure that individual patients receive the drug that is most likely to be effective, stated the inventors, Drs. Rimm and Camp. In addition, we believe this technology will provide the pathologist with significantly enhanced and valuable information for diagnosis and prognosis of cancer and other complex diseases.

HistoRx is developing and commercializing pioneering quantitative histopathology technology that provides exceptional measurement and localization of protein biomarkers in their natural context within tissue. The Aqua technology is capable of measuring biomarker concentration with subcellular resolution to generate more precise, efficient, and cost-effective answers about the safety and effectiveness of new therapeutics in development as well as enable the development of companion diagnostic tests for targeted therapies.

HistoRx is also developing independent diagnostics using Aqua technology that will utilize the multiparametric approach offered by the technology to impact prognosis and treatment decisions of complex diseases.


Related Links:
Yale University
HistoRx

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Drug Testing Assays
Atellica DT 250 Analyzer
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.